This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-03. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
The volunteer distributed computing project Folding@home simulates protein folding. It was used for medical research. In March 2020 it became the world's first system to reach one exaFLOPS and reached approximately 2.43 x86 exaFLOPS by 13 April 2020 – many times faster than Summit, the fastest supercomputer of that time. That month Rosetta@home joined the effort. Researchers announced that Rosetta@home allowed them to "accurately predict the atomic-scale structure of an important coronavirus protein weeks before it could be measured in the lab." In May 2020, the OpenPandemics—COVID-19 partnership was launched between Scripps Research and IBM's World Community Grid. The partnership is a distributed computing project that "will automatically run a simulated experiment in the background [of connected home PCs] that will help predict the efficacy of a particular chemical compound as a potential treatment for COVID-19."
=== Structure of graphite and its intercalation compounds === In 1859, Benjamin Brodie noted the highly lamellar structure of thermally reduced graphite oxide. Researchers used X-ray crystallography in an attempt to determine the structure of graphite. The lack of large single crystal graphite specimens contributed to the independent development of X-ray powder diffraction by Peter Debye and Paul Scherrer in 1915, and Albert Hull in 1916. However, neither of their proposed structures was correct. In 1918, Volkmar Kohlschütter and P. Haenni described the properties of graphite oxide paper. The structure of graphite was successfully determined from single-crystal X-ray diffraction by J. D. Bernal in 1924, while subsequent research tweaked the unit cell parameters. The theory of graphene was first explored by P. R. Wallace in 1947 as a starting point for understanding the electronic properties of 3D graphite. The emergent massless Dirac equation was separately pointed out in 1984 by Gordon Walter Semenoff, and by David P. Vincenzo and Eugene J. Mele. Semenoff emphasized the occurrence in a magnetic field of an electronic Landau level precisely at the Dirac point. This level is responsible for the anomalous integer Quantum Hall effect.
==== Rentosertib ==== Rentosertib is an investigational new drug that targets TNIK (TRAF2 and NCK-interacting protein kinase). It is asserted to be the first drug generated entirely by generative AI to reach mid-stage human clinical trials, and the first to target a novel AI-discovered biological pathway. A multicenter, double-blind, placebo-controlled, randomized phase 2a trial was conducted in China, testing the drug in 71 IPF patients from July 2023 to June 2024, encompassing an administration period of 12 weeks. Participants were randomly assigned to receive 30 mg once daily (QD), 30 mg twice daily (BID), 60 mg QD, or placebo. The trial's primary endpoint was the incidence of treatment-emergent adverse events (TEAEs).
Because water-soluble B vitamins are eliminated in the urine, taking large doses of most B vitamins usually only produces transient side effects (with the only exception being pyridoxine). General side effects may include restlessness, nausea, and insomnia. These side effects are almost always caused by dietary supplements and not food.
Strontium ranelate – may decrease degeneration in osteoarthritis and improve outcomes Gene therapy – Gene transfer strategies aim to target the disease process rather than the symptoms. Cell-mediated gene therapy is also being studied. One version was approved in South Korea for the treatment of moderate knee osteoarthritis; however, this was cancelled after it was discovered that the approval application and list of ingredients were misleading. The drug was administered intra-articularly. The anti-IL-1β monoclonal antibody canakinumab showed a reduced incidence of knee and hip replacements in those with osteoarthritis in a long term trial. IL-1β is a cytokine involved in joint destruction in osteoarthritis.
Sources: en.wikipedia.org
== In film and popular culture == The 1987 comedy Spaceballs features a character named Pizza the Hutt, which is a parody of Jabba the Hutt made to sound like Pizza Hutt. In the 1989 film Back to the Future Part II, Marty McFly and his family eat a "rehydrated" Pizza Hut pizza in the futuristic 2015. The 1992 film Wayne's World features a scene where Wayne, played by Mike Myers, tells the audience that he will not be bought by corporate sponsors while eating a slice of Pizza Hut pizza. There is a scene set in a Pizza Hut in the 2011 romantic comedy Just Go With It. In the 2014 Teenage Mutant Ninja Turtles film, pizza boxes from Pizza Hut are prominently displayed in the group's sewer lair. The film Slice of Life: The American Dream. In Former Pizza Huts, directed by Matthew Salleh and released in 2024, is a documentary about people who have converted former Pizza Hut buildings across America into a variety of new enterprises.
==== Hodgkin-Huxley Model ==== The Hodgkin–Huxley model translates data about the current of a system at a specific voltage into time-dependent data describing the membrane potential. Experiments using this model typically rely on the same format and assumptions, but vary the differential equations to answer their particular questions. Much has been learned about vasopressin, GnRH, somatotrophs, corticotrophs, and lactotrophic hormones by employing this method.
=== Occurrence in bacteria === Hydrogen cyanide is produced by various soil bacteria, including cyanobacteria and representatives of the genera Aeromonas, Bacillus, and Pseudomonas. Biosynthesis proceeds from glycine. A group of alkanenitriles was isolated from Pseudomonas veronii: dodecannitrile, tridecannitrile, tetradecanenitrile, pentadecannitrile, and hexadecannitrile, as well as compounds of similar chain length containing a double bond. From Micromonospora echinospora, structurally related compounds were also isolated, differing by a terminal methyl branch, a double bond, or both. A cyanohydrin containing a phosphonic acid moiety is known from Streptomyces regensis. The aetokthonotoxin from the cyanobacteria Aetokthonos hydrillicola is a brominated indole derivative bearing a nitrile group. It is a potent neurotoxin that frequently causes mortality in bald eagles that ingest it.
== Biological activity == Amines are ubiquitous in biology. The breakdown of amino acids releases amines, famously in the case of decaying fish which smell of trimethylamine. Many neurotransmitters are amines, including epinephrine, norepinephrine, dopamine, serotonin, and histamine. Protonated amino groups (–NH+3) are the most common positively charged moieties in proteins, specifically in the amino acid lysine. The anionic polymer DNA is typically bound to various amine-rich proteins. Additionally, the terminal charged primary ammonium on lysine forms salt bridges with carboxylate groups of other amino acids in polypeptides, which is one of the primary influences on the three-dimensional structures of proteins.
=== Reference analytical values === Analytical values take as reference for genuinity evaluation of bergamot essential oil by the Experimental Station for the Industry of the Essential oils and Citrus products, in Reggio Calabria, Italy.
Sources: en.wikipedia.org
When cells on one side of a stem grow longer and faster than cells on the other side, the stem will bend to the side of the slower growing cells as a result. This directional growth can occur via a plant's response to a particular stimulus, such as light (phototropism), gravity (gravitropism), water, (hydrotropism), and physical contact (thigmotropism). Plant growth and development are mediated by specific plant hormones and plant growth regulators (PGRs) (Ross et al. 1983). Endogenous hormone levels are influenced by plant age, cold hardiness, dormancy, and other metabolic conditions; photoperiod, drought, temperature, and other external environmental conditions; and exogenous sources of PGRs, e.g., externally applied and of rhizospheric origin.
Unlike other Dexcom models, Stelo is available over the counter and does not require a prescription. As of December 1, 2025, both the Dexcom G7 15-Day; G7 and Stelo are available in the U.S. market, only the G7 and Stelo are available internationally.
Menkes disease is a congenital disease that is a cause of copper deficiency. Menkes disease is a hereditary condition caused by a defective gene involved with the metabolism of copper in the body. Menkes disease has a wide variety of symptoms including floppy muscle tone, seizures, abnormally low body temperature, and a peculiar steel color hair that feels very rough. Menkes disease is usually fatal, with the majority of affected children dying within the first ten years of life.
== Road closure == An ice road will typically be closed as a result of deterioration of the running or operating surface, before there is any risk of ice cover failure. Surface deterioration can happen when the ice surface becomes too soft, or because of an excessive amount of meltwater on its surface. Mid-season road closures can also happen for similar reasons, and also because of inclement weather, such as a blizzard. If the ice road is part of a winter road, then closure can also be due to an over-land segment that has become unserviceable.
An over-active renin-angiotensin system leads to vasoconstriction and retention of sodium and water. These effects lead to hypertension. Therefore, renin inhibitors can be used for the treatment of hypertension. This is measured by the plasma renin activity (PRA). In current medical practice, the renin–angiotensin–aldosterone system's overactivity (and resultant hypertension) is more commonly reduced using either ACE inhibitors (such as ramipril and perindopril) or angiotensin II receptor blockers (ARBs, such as losartan, irbesartan or candesartan) rather than a direct oral renin inhibitor. ACE inhibitors or ARBs are also part of the standard treatment after a heart attack. The differential diagnosis of kidney cancer in a young patient with hypertension includes juxtaglomerular cell tumor (reninoma), Wilms' tumor, and renal cell carcinoma, all of which may produce renin.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.